GnRH analogues (GnRHa) represent the treatment of choice in central precocious puberty (CPP), because arresting pubertal development and reducing either growth velocity (GV) or bone maturation (BA) should improve adult height. However, in some patients, GV decrease is so remarkable that it impairs predicted adult height (PAH); and therefore, the addition of GH is suggested. Out of twenty subjects with idiopathic CPP (treated with GnRHa depot-triptorelin, at a dose of 100 g/kg im every 21 days, for at least 2-3 yr), whose GV fall below the 25th percentile for chronological age, 10 received, in addition to GnRHa, GH at a dose of 0.3 mg/kg⅐week sc, 6 days weekly, for 2-4 yr; and 10 matched for BA, chronological age, and duration of GnRHa treatment, who showed the same growth pattern but refused GH treatment, served to evaluate the efficacy of GH addition. No patient showed classical GH deficiency. Both groups discontinued treatment at a comparable BA (mean Ϯ SEM): 13.2 Ϯ 0.2 in GnRHa plus GH vs. 13.0 Ϯ 0.1 yr in the control group. At the conclusion of the study, all the patients had achieved adult height. Adult height was considered to be attained when the growth during the preceding year was less than 1 cm, with a BA of over 15 yr. Patients of the group treated with GH plus GnRHa showed an adult height significantly higher (P Ͻ 0.001) than pretreatment PAH (160.6 Ϯ 1.3 vs. 152.7 Ϯ
G nRH ANALOGUES (GnRHa) represent the treatment of choice in central precocious puberty (CPP), because arresting pubertal development and reducing either growth velocity (GV) or bone maturation (BA) should improve adult height (1) (2) (3) (4) (5) (6) (7) (8) (9) . However, in some patients, GV decrease is so remarkable that predicted adult height (PAH) is impaired (10, 11) ; and therefore, some investigators suggest, on the basis of several (though controversial) studies on GH secretion in this subset of CPP patients (12) (13) (14) (15) (16) , the combination of GnRHa with GH (17) (18) (19) (20) (21) .
We report here the adult height of a group of 10 girls with idiopathic CPP treated with combined therapy, compared with that of 10 CPP girls matched for auxological data, duration of treatment, and severe growth deceleration treated with GnRHa alone.
Subjects and Methods Subjects
Ten girls with idiopathic CPP, diagnosed according to the classic criteria (22) , whose GV during GnRHa treatment (depot-Triptorelin, 100 g/kg every 21 days im) decreased below the 25th centile for chronological age (CA), with no improvement in PAH, received GH at a dose of 0.3 mg/kg⅐week sc 6 days weekly for 3.07 Ϯ 1.33 yr (Group 1). Auxological data at diagnosis, at the start of GnRHa therapy, at the start of GnRHaϩGH therapy, and at the end of treatment and adult height are shown in Table 1 . The GV decrease (from 8.3 Ϯ 0.8 to 3.8 Ϯ 0.4 cm/yr) was observed after 2-3 yr of GnRHa treatment, and GH was given at the third year.
Ten girls with idiopathic CPP (matched for BA, CA, and duration of GnRHa treatment), who showed a similar deceleration of growth (below the 25th centile for CA) at comparable times, did not receive GH treatment; and their data were used in comparison to better evaluate the efficacy of GH addition (Group 2). Their auxological data are shown in Table 2 .
All patients were euthyroid; GH secretory status has been studied at the time of growth deceleration. Twelve patients underwent GH stimulation tests (arginine, l-dopa) and showed a normal GH response, with a peak more than 10 g/L; in the remaining eight patients, evaluation of spontaneous GH secretion was performed by measuring GH in blood sampled every 20 min from 2000 h to 0800 h: the mean value (mean Ϯ sd) was 5.8
The study was approved by the Ethical Committee of our institution; written consent was obtained from parents of children who received GH. Both groups of patients were evaluated at the start of treatment and every 6 months, either during the course of treatment or after the withdrawal. At each evaluation, height was measured three times with a Harpenden stadiometer. Bone age was determined according to the method of Greulich and Pyle (23) by the same observer, and adult height was predicted according to the Bayley and Pinneau method (24) . Pubertal staging was evaluated using the method of Tanner (25, 26) . Plasma samples, for determination of sex steroid levels, were obtained every 6 months; and gonadotropins were evaluated every 6 months after the iv administration of 100 g of LH-releasing hormone (LHRH) (sampling at 15 and 0 min before and 15, 30, 60, 90, and 120 min after LHRH); the LHRH stimulation test was performed on day 20 after injection of the GnRHa. Screening blood tests (to assess metabolic, hepatic, renal, hematological, and thyroid function) were also performed at each evaluation. In addition, an oral glucose tolerance test was performed every 12 months in the patients receiving GnRHaϩGH treatment. Pelvic ultrasound, to evaluate uterine and ovarian volumes, was performed every 6 months. Midparental TH was calculated from the mean height of the parents, adjusted for sex, as described by Tanner et al. (27) .
Both groups discontinued treatment at a comparable bone age and CA: BA (mean Ϯ sem), 13.2 Ϯ 0.2 in GnRHa plus GH vs. 13.0 Ϯ 0.1 yr in the GnRHa-alone group; and CA (mean Ϯ sem), 13 Ϯ 0.4 vs. 12.5 Ϯ 0.4 yr. At present, all the patients of this study achieved adult height. Adult height was considered to be attained when the growth during the preceding year was less than 1 cm, with a BA of over 15 yr.
GH was discontinued contemporaneously with GnRHa, regardless of the current criteria of withdrawal (i.e. GV less than 2 cm/yr and BA Ն 14 yr).
Hormone assay
Plasma LH and FSH were measured in duplicate by immmunoradiometric assay (Maiaclone, Serono Biodata, Milan, Italy); estradiol was measured by RIA (DPC, Los Angeles, CA; Bio-Rad, Hercules, CA); GH was measured in duplicate by policlonal RIA (Sorin Biomedica, Vercelli, Italy).
Statistical analysis
Data are expressed as mean sem unless otherwise stated. Statistical analysis was performed by the paired and unpaired Student's t test and ANOVA. A P value Ͻ 0.05 was considered significant.
Results
No side effects or changes in suppression of the hypothalamic-pituitary-gonadal axis were observed during the combined GnRHaϩGH treatment. Plasma FSH and LH peaks after the LHRH test were suppressed during treatment, significantly lower than pretreatment, both in the GnRHaϩGH-treated group (peak LH: 0.61 Ϯ 0.17 vs. 26.7 Ϯ 2.8 IU/L, peak FSH: 1.4 Ϯ 0.08 vs. 12.5 Ϯ 0.86 IU/L, both P Ͻ 0.05) and in the GnRHa-alone-treated group (peak LH: 0.76 Ϯ 0.17 vs. 26.7 Ϯ 5.5 IU/L, peak FSH: 1.0 Ϯ 0.2 vs. 17.0 Ϯ 2.5 IU/L, both P Ͻ 0.05). After the withdrawal of treatment, peak LH rose back to 14.22 Ϯ 5.7 and FSH peak to 10.58 Ϯ 2.17 IU/L within 1 yr in the combined group; and peak LH arose to 11.87 Ϯ 2.9 and FSH peak 9.13 Ϯ 0.92 IU/L within a similar period in the GnRHa-alone-treated group (P Ͻ 0.05).
We did not observe abnormal advancement in bone age or untoward side effects in the GH-treated group; BA progressed with the same velocity until epiphyseal closure after discontinuation of treatment without any significant difference between the two groups.
On treatment, pelvic ultrasound showed reduced ovarian volume in both groups; and ovarian cyst appearance, previously described by some authors (28), was not observed in GH-treated girls. Ovarian volumes were reduced from 3.08 Ϯ 0.36 to 1.78 Ϯ 0.19 during treatment, increased to 5.66 Ϯ 0.24 cm3 (P Ͻ 0.05) after 1 yr off therapy in the GnRHaϩGH-treated group. Similarly, in the GnRHa-alonetreated group, ovarian volumes during therapy reduced from 2.33 Ϯ 0.36 to 1.59 Ϯ 0.12 and increased to 4.64 Ϯ 0.48 cm3 (P Ͻ 0.05) after 1 yr without therapy, showing a similar increment. No significant difference was found between ovarian volumes of both groups at 1 yr without treatment. The uterine length remained unchanged during treatment (from 4.7 Ϯ 0.39 to 4.5 Ϯ 0.2 cm) and increased to 6.3 Ϯ 0.29 cm (P Ͻ 0.05) after 1 yr off therapy in the GnRHaϩGH-treated group. Similarly, in the GnRHa-alone-treated group, uterine length remained unchanged during therapy (from 4.2 Ϯ 0.22 to 4.2 Ϯ 0.13 cm) and increased to 5.72 Ϯ 0.29 cm (P Ͻ 0.05) after 1 yr without therapy, showing a comparable increment.
In both groups, menarche occurred in coincidence with the resumption of FSH and LH secretion; and increments of ovarian volumes and uterine length occurred about 8 -18 months (average 1 yr) after the discontinuation of therapy. Subsequent menses were regular, without any difference between the two groups, at least at present, after a further year of observation.
As for group 1, PAH at the start of GnRHa-alone treatment (152.7 Ϯ 1.7 cm) was not significantly different from PAH at the start of GnRHaϩGH treatment (153.5 Ϯ 1.7 cm), and it increased significantly to 163.2 Ϯ 1.7 cm at the end of com- bined therapy (P Ͻ 0.001). Adult height was 160.6 Ϯ 1.3 cm, remaining significantly higher (P Ͻ 0.001) than pretreatment PAH and not significantly lower (P ϭ not significant) than PAH at the end of treatment. TH was significantly exceeded (P Ͻ 0.05) ( Table 1) . As for group 2, PAH at the start of GnRHa alone was 155.5 Ϯ 2.0 and increased to 159.6 Ϯ 2.3 cm at the end of treatment [still significantly, but to a lesser extent than in group 1 (P Ͻ 0.01)]. Adult height in these patients was not significantly higher than pretreatment PAH (157.1 Ϯ 2.5 vs. 155.5 Ϯ 1.9 cm). TH was reached but not exceeded (P ϭ not significant) ( Table 2) .
Discussion
Idiopathic CPP includes a heterogeneous group of patients differing in age, bone age, genetic factors determining height, and associated conditions. Perhaps for these reasons, a subset of these patients shows a worse response to GnRHa. Beside a variable implication of GH secretion, which is not classically deficient in some patients like ours, the addition of growth hormone to GnRHa has been suggested by some authors, for these patients and even for short normal subjects with early or normal puberty (29, 30) . Because, in our patients, GH was not classically deficient, we used a dose higher than the replacement GH dose, on the basis of the same rationale used in short normal children (31, 32) .
The gain in centimeters obtained in our study, calculated between pretreatment PAH (152.7 Ϯ 1.7) and final height (160.6 Ϯ 1.3 cm), was 7.9 cm Ϯ 1.1 in patients treated with GHϩGnRHa, whereas in patients treated with GnRHa alone, the gain between pretreatment PAH (155.5 Ϯ 1.7) and final height (157.1 Ϯ 2.5 cm) was just 1.6 cm Ϯ 1.2. The difference between the gain obtained in the groups is significant, in favor of group 1 (P ϭ 0.001).
Thus, final results of our experience show that the gain calculated just on PAH decreased when adult height was attained and compared with pretreatment PAH in both groups. In the same patients, we previously reported results at 3 yr (20) , showing a mean gain of 13.5 cm in PAH in the GHϩGnRHa group, which became 7.9 cm as adult height; and of 6 cm in the GnRHa-alone group, which became 1.6 cm as adult height. This could be caused by the limits of height prediction methods, based on bone ages at the beginning, accelerated by precocious puberty, and afterward decelerated by treatment (9) . Another reason of loss in centimeters, in group 1, could be our protocol design, which stipulated discontinuation of GH contemporaneously with GnRHa, regardless of current criteria for GH discontinuation (i.e. GV less than 2 cm/yr and bone age Ն 14 yr).
However, a gain of 7.9 cm in adult height represents a significant improvement, which justifies the addition of GH for 2-3 yr during the conventional treatment with GnRHa, especially in patients with CPP and a decrease in GV, so marked as to impair PAH, not allowed to reach even the third centile.
Furthermore, no adverse effects, either on bone age or on ovarian morphology and function, have been observed. Bone age progressed at the same rate in both groups, and menarche occurred about 1 yr after discontinuation of treatment.
Subsequent menses were regular, and no ovarian cysts appeared, so far. In conclusion, TH was significantly exceeded by patients treated with combined therapy.
Based on our data, the most propitious strategy for optimal treatment (especially in girls with CPP with a very short PAH) can be to prolong the GH administration after GnRHa discontinuation, until the closure of epiphyses, to sustain growth during the residual pubertal spurt, as suggested in a study on short normal girls treated with GHϩGnRHa (29) .
